Durlobactam is a non-beta-lactam, beta-lactamase inhibitor used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. It is typically given in combination with sulbactam to protect it from degradation by certain serine-beta-lactamases.
- Mechanism
- Curator reviewed · 2 references
Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. When given in combination with sulbactam, it protects sulbactam from degradation by certain serine-beta-lactamases. Durlobactam is carbamoylated by β-lactamase by the serine nucleophile in the enzyme active site: The covalent bond between durlobactam and β-lactamase is reversible due to recyclization by the sulfated amine group on durlobactam, demonstrating that durlobactam can be exchanged from one enzyme molecule to another, also known as acylation exchange.
- Primary indication
- In combination with sulbactam, durlobactam is indicated in adults for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.Curator reviewed · 2 structured indications
- Formula / weight
- C8H11N3O6S · 277.25 g/mol (avg)
- First approval
- United States, 2023
- Also known as
- (2S,5R)-2-CARBAMOYL-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL SULFATE · SULFURIC ACID, MONO((2S,5R)-2-(AMINOCARBONYL)-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL) ESTER
- Code names
- ETX-2514 · WHO 10824
- Brand names
Resolves to
BISPBXFUKNXOQY-RITPCOANSA-NSMILESCC1=C[C@@H]2C[N@]([C@@H]1C(N)=O)C(=O)N2OS(O)(=O)=OWhat you can answer from here — as of September 13, 2026
Which other approved drugs treat the same conditions as Durlobactam, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account